Docetaxel 80 mg concentrate for solution for infusion, 1 vial (KOCAK ILAC Turkey) Breast cancer. Targeted cancer therapy. Delivery of medications from Europe and elsewhere within 4-5 days. Storage conditions are met. Payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Indications

• Breast cancer. Taxotere ® in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
• operable node-positive breast cancer
• operable node-negative breast cancer.
• Patients with operable node-negative breast cancer should receive adjuvant therapy if they are eligible for chemotherapy according to accepted international criteria for the primary therapy of early-stage breast cancer.
• Taxotere ® in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this disease.
• Taxotere ® as monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy, which included anthracycline or alkylating agents. drug.
• Taxotere ® in combination with trastuzumab is intended for the treatment of patients with metastatic breast cancer with increased expression of HER-2 by tumor cells who have not previously received chemotherapy for metastases.
• Taxotere ® in combination with capecitabine is intended for the treatment of patients with locally advanced or metastatic breast cancer after ineffective therapy that included anthracycline.
•  
• Non-small cell lung cancer. Taxotere ® is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after chemotherapy failure.
• Taxotere ® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced, or metastatic non-small cell lung cancer who have not received previous chemotherapy for this condition.
• Prostate Cancer Taxotere ® in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.
• Gastric adenocarcinoma. Taxotere ® in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including gastroesophageal adenocarcinoma, who have not previously received chemotherapy for metastases.
• Head and Neck Cancer. Taxotere ® in combination with cisplatin and 5-fluorouracil